SecBot SecBot
SECBOTREPLAY Home › Report › LGND

LGND · Ligand reported Q2 2026 adjusted EPS of $2.37, a 20.3% beat vs…

LIGAND PHARMACEUTICALS INC · 8-K filed Aug 6, 2026 at 07:05 ET

At the news

BULLISHIMPACT 7/10

8-K filed Aug 6, 2026 at 07:05 ET

Ligand reported Q2 2026 adjusted EPS of $2.37, a 20.3% beat vs consensus of $1.97, driven by 32% YoY royalty revenue growth to $48.0M. The company raised the low end of its 2026 adjusted EPS guidance to $9.00-$9.50 (from $8.50-$9.50) and closed the XOMA Royalty acquisition on July 14, 2026, adding over 120 assets. The strong beat, guidance raise, and transformative acquisition close are clearly positive, but the $700M convertible debt issuance and share repurchase at ~$262 introduce modest dilution and capital structure complexity.

  • Q2 2026 adjusted EPS of $2.37 beat consensus of $1.97 by 20.3%
  • Q2 2026 total revenue of $63.7M beat consensus of $61.3M by 3.9%
  • Royalty revenue grew 32% YoY to $48.0M, driven by Filspari, Zelsuvmi, and Ohtuvayre
  • Raised low end of 2026 adjusted EPS guidance to $9.00-$9.50 (from $8.50-$9.50); revenue guidance unchanged at $270M-$310M

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access